Guest Artist Recital:Stephen Swedish, Piano

Kemp Recital Hall Wednesday Evening February 28, 2001 8:00p.m

Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease

β-Blockers reduce mortality and improve symptoms in people with heart disease. However, current clinically available β-blockers have poor selectivity for the cardiac β1-adrenoceptor (AR) over the lung β2-AR. Unwanted β2-blockade risks causing life-threatening bronchospasm and a reduction in the efficacy of β2-agonist emergency rescue therapy. Thus current life-prolonging β-blockers are contraindicated in people with both heart disease and asthma. Here we describe NDD-713 and NDD-825, novel highly β1-selective neutral antagonists with good pharmaceutical properties that can potentially overcome this limitation. Radioligand binding studies and functional assays using human receptors expressed in CHO cells demonstrate that NDD-713 and NDD-825 have nanomolar β1-AR affinity, greater than 500-fold β1-AR vs β2-AR selectivity and no agonism. Studies in conscious rats demonstrated that they are orally bioavailable and cause pronounced β1-mediated reduction of heart rate while showing no effect on β2-mediated hindquarters vasodilatation. The compounds also have good disposition properties and show no adverse toxicological effects. They potentially offer a truly cardioselective β-blocker therapy for the large number of people with heart and respiratory, or peripheral vascular comorbidities

Commentary on 'What is the point: will screening mammography save my life?' by Keen and Keen

Commentary on Keen and Keen 'What is the point: will screening mammography save my life?' BMC Medical Informatics and Decision Making, 200

Sick Leave and Work Participation Among Parents of Children with Autism Spectrum Disorder in the Stockholm Youth Cohort: A Register Linkage Study in Stockholm, Sweden

This population-based register study explored the association between having a child with/without autism spectrum disorder (ASD) and parental sick leave and work participation. Parents of children with ASD living in Stockholm, Sweden in 2006 were more likely to be on sick leave, not in the labor force, or earning low income when compared to parents who did not have a child with ASD and these results remained after adjusting for familial socioeconomic factors and parental psychiatric care. Sick leave among parents was associated with having a child with ASD without intellectual disability (ID) but not ASD with ID. Although Sweden has policies helping families with children with ASD this study suggests that there exist unmet needs among these parents

Reel 2

Instrumentation: pian

Searches for new resonances decaying to top-antitop quark pairs with the ATLAS detector in sqrt(s) = 7 TeV proton-proton collisions

This work presents the results of two analyses searching for massive resonances decaying to top-antitop quark pairs in sqrt(s) = 7 TeV proton-proton collisions measured with the ATLAS detector at the CERN Large Hadron Collider. The peculiar position of the top-quark within the Standard Model, as the most massive particle, motivates many theories predicting the existence of new massive particles that couple strongly to top-quarks. These particles may manifest themselves at the LHC as new massive resonances decaying to top-antitop quark pairs. An analysis conducted on the first 2.04/fb^-¹ of data collected in 2011 searched for resonances in the subset of top-pair events where the W-bosons from each top decay decayed leptonically to a final state electron or muon. A second analysis conducted on the full 4.7/fb^-¹ of 2011 data searched for resonances in the subset of top-quark pair events where W-bosons from each top decay decayed hadronically to a diquark pair. The analysis focused on the case were each top-quark is sufficiently boosted such that the resultant fully hadronic system is highly collimated, and reconstructable as a single hadronic jet with large angular separation. In each analysis, the leptophobic Z' from topcolor assisted technicolor models, and the KK-gluon from Randall-Sundrum warped extra-dimension models were chosen as benchmarks to test for the presence of narrow and wide resonances respectively. No significant deviation from the Standard Model was observed in either analysis. The results were used to set 95% C.L. upper limits on the cross-section times branching ratio to top-quark pairs as a function of resonance mass for each benchmark model. The existence of a Randall-Sundrum KK-gluon was excluded at the 95% C.L. over the mass range 500 to 1620 GeV.Science, Faculty ofPhysics and Astronomy, Department ofGraduat

Arts in April

Sonata in E-flat Major, Hob. XVI: 49 (Haydn, Joseph); Images, Book 1 (Debussy, Claude); Canteyodjaya (Messiaen, Olivier); Sonata in B Minor (Liszt, Franz). Instrumentation: pian

45. Is there potential for use of the quadrivalent HPV vaccine as a post-treatment adjuvant?

Background The quadrivalent HPV (qHPV) vaccine (Gardasil®; Merck and Co., Whitehouse Station, NJ) is licensed to prevent anorectal HPV related disease in men and women through age 26 years. We demonstrated previously that qHPV was associated with decreased risk of recurrent HSIL among men who have sex with men (MSM; HR 0.50, 95% CI 0.26–0.98; P = 0.04). We endeavoured to determine if qHPV was effective in preventing condyloma development and recurrence in older MSM patients. Methods: A non-concurrent cohort study of patients vaccinated with qHPV compared with non-vaccinated patients. Those with a history of condyloma were disease free for 1 year. Results: 313 patients with a mean age of 42 years were followed for a median of 981 days. During 773.6 person-years follow-up, condyloma developed in 10 (8.6%) vaccinated patients (incidence 3.7 per 100 person-years) and 37 (18.8%) unvaccinated patients (incidence 7.3 per 100 person-years; P = 0.05). Multivariable hazards ratio showed that qHPV was associated with decreased risk of anal condyloma development (HR 0.45; 95% CI 0.22–0.92; P = 0.03). Kaplan–Meier (KM) survival analysis showed significantly reduced recurrence out to 4 years (cumulative incidence vaccinated 0.1 vs unvaccinated 0.25; P = 0.04). In the smaller subset of 103 patients with a history of condyloma, KM survival analysis showed striking separation of curves in the vaccinated vs unvaccinated with the cumulative incidence of recurrence (0.15, 0.35, respectively) but it did not reach significance (P = 0.12). Conclusions: The qHPV vaccine appears to prevent incident and recurrent condyloma in patients older than 26 years and might be a useful post treatment adjuvant. </jats:p